Hydrocortisone Acetate Rectal Foam / Enema
Brand names: Colifoam (foam), Hydrocortisone Enema
Hydrocortisone acetate rectal foam (or enema) is a topical corticosteroid preparation used to treat inflammation in the rectum and lower colon, such as in distal ulcerative colitis and proctitis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Delivered locally to the rectal and distal colonic mucosa, hydrocortisone exerts anti-inflammatory and immunosuppressive effects that reduce mucosal inflammation with limited systemic absorption.
Prescribing in practice
- Although topical, some systemic absorption occurs, so prolonged or high-frequency use can cause adrenal suppression and other corticosteroid effects and treatment should not be stopped abruptly after extended use.
- It is contraindicated where rectal corticosteroids are inappropriate, such as bowel obstruction, perforation or untreated local infection including fungal infection.
- The foam formulation can be easier to retain and may reach a more limited extent of bowel than a liquid enema, so choose the formulation to match disease location.
Monitoring
For short courses little monitoring is needed, but with prolonged use be alert to features of systemic corticosteroid exposure and adrenal suppression.
Counselling the patient
- Use the applicator as directed and try to retain the foam or enema to allow it to act on the inflamed bowel.
- Do not stop suddenly if you have used it for a prolonged period; follow the team's advice on tapering.
Evidence & guidelines
Topical rectal corticosteroids are recommended in NICE guidance as an option for active distal ulcerative colitis and proctitis.
Reference: BSG Ulcerative Colitis Guidelines 2019; SPC Colifoam; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021